Research programme: kinase modulators - Blueprint Medicines

Drug Profile

Research programme: kinase modulators - Blueprint Medicines

Alternative Names: BLU 6864; BLU 9931; BLU-667; c-KIT D816V inhibitor - Blueprint Medicines; Fibroblast growth factor receptor 4 (FGFR4) selective inhibitor - Blueprint Medicines; Highly selective kinase drugs for specific genomically-defined cancer patients - Blueprint Medicines; Kinase inhibitors - Blueprint Medicines; KIT D816V selective inhibitor - Blueprint Medicines; NTRK inhibitors; Phosphotransferase inhibitors - Blueprint Medicines; PRKACA inhibitors - Blueprint Medicines; Protein kinase cAMP-activated catalytic subunit alpha (PRKACA) fusions inhibitors; RET fusion inhibitors - Blueprint Medicines; RET inhibitors - Blueprint Medicines; TrkA inhibitors; Type 4 fibroblast growth factor receptor (FGFR4) antagonists - Blueprint Medicines

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Blueprint Medicines
  • Class Small molecules
  • Mechanism of Action Advanced glycosylation end product modulators; Fusion oncogene protein inhibitors; Phosphotransferase inhibitors; Protein kinase inhibitors; Protein kinase modulators; Proto oncogene protein c-kit inhibitors; Receptor protein-tyrosine kinase antagonists; TrkA receptor antagonists; Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Gastrointestinal stromal tumours; Hepatocellular carcinoma; Mastocytosis; Non-small cell lung cancer; Thyroid cancer
  • Research Inborn genetic disorders

Most Recent Events

  • 27 Jan 2017 Blueprint Medicines Corporation plans a first-in-human phase I trial for Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable, Metastatic disease), Thyroid cancer and Solid tumours (Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable) in USA (PO) (NCT03037385)
  • 17 Mar 2016 Interim pharmacodynamics data from preclinical studies in Cancer released by Blueprint Medicines
  • 15 Mar 2016 Blueprint Medicines and Roche enter into a worldwide collaboration and exclusive license agreement for the discovery, development and commercialization of up to five small molecule therapeutics targeting kinases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top